Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
PfizerPFE |
$440,000 |
 |
Johnson & JohnsonJNJ |
-$120M |
 |
Mind Medicine (MindMed)MNMD |
-$86M |
 |
ModernaMRNA |
-$37.4B |
 |
Eli Lilly and CompanyLLY |
-$334,594B |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| SALEKI-GERHARDT AZITA | Aug 12, 2025 | Sell | 42,370 | $198.42 | $8.4M |
| Donoghoe Nicholas | Aug 5, 2025 | Sell | 3,234 | $198.27 | $640,000 |
| Donoghoe Nicholas | Aug 5, 2025 | Sell | 10,061 | $198.59 | $2M |
| Stewart Jeffrey Ryan | Mar 31, 2025 | Sell | 33,132 | $210.54 | $7M |
| Stewart Jeffrey Ryan | Mar 31, 2025 | Sell | 25,700 | $209.49 | $5.4M |
| Reents Scott T | Mar 14, 2025 | Sell | 17,644 | $212.34 | $3.7M |
| RICHMOND TIMOTHY J. | Mar 3, 2025 | Sell | 600 | $211.32 | $130,000 |
| RICHMOND TIMOTHY J. | Mar 3, 2025 | Sell | 5,677 | $209.8 | $1.2M |
| RICHMOND TIMOTHY J. | Mar 3, 2025 | Sell | 14,973 | $210.66 | $3.2M |
| Siatis Perry C | Mar 3, 2025 | Sell | 18,008 | $210 | $3.8M |
| GONZALEZ RICHARD A | Mar 3, 2025 | Sell | 6,168 | $210.53 | $1.3M |
| Siatis Perry C | Feb 28, 2025 | Sell | 2,718 | $205.38 | $560,000 |
| Siatis Perry C | Feb 28, 2025 | Sell | 363 | $207.19 | $75,000 |
| Siatis Perry C | Feb 28, 2025 | Sell | 6,811 | $206.62 | $1.4M |
| GONZALEZ RICHARD A | Feb 28, 2025 | Sell | 92,460 | $205.11 | $19M |
| RICHMOND TIMOTHY J. | Feb 26, 2025 | Sell | 4,781 | $202.93 | $970,000 |
| RICHMOND TIMOTHY J. | Feb 26, 2025 | Sell | 1,400 | $202.06 | $280,000 |
| RICHMOND TIMOTHY J. | Feb 26, 2025 | Sell | 1,526 | $203.64 | $310,000 |
| RICHMOND TIMOTHY J. | Feb 26, 2025 | Sell | 4,308 | $201.97 | $870,000 |
| RICHMOND TIMOTHY J. | Feb 26, 2025 | Sell | 4,829 | $203.63 | $980,000 |
| Buckbee Kevin K | Feb 26, 2025 | Sell | 16,260 | $203.41 | $3.3M |
| Buckbee Kevin K | Feb 26, 2025 | Sell | 2,684 | $203.4 | $550,000 |
| RICHMOND TIMOTHY J. | Feb 26, 2025 | Sell | 13,073 | $202.92 | $2.7M |
| Siatis Perry C | Feb 20, 2025 | Sell | 3,994 | $198.12 | $790,000 |
| Siatis Perry C | Feb 20, 2025 | Sell | 1,784 | $197.4 | $350,000 |
| Buckbee Kevin K | Dec 16, 2024 | Sell | 1,800 | $172.24 | $310,000 |
| GONZALEZ RICHARD A | Aug 5, 2024 | Sell | 66,500 | $186.52 | $12M |
| GONZALEZ RICHARD A | Jul 17, 2024 | Sell | 282,845 | $175 | $49M |
| Donoghoe Nicholas | Mar 20, 2024 | Sell | 21,082 | $176.3 | $3.7M |
| Stewart Jeffrey Ryan | Mar 18, 2024 | Sell | 5,099 | $179.03 | $910,000 |
| Stewart Jeffrey Ryan | Mar 18, 2024 | Sell | 27,740 | $178.69 | $5M |
| Stewart Jeffrey Ryan | Mar 18, 2024 | Sell | 26,110 | $178.85 | $4.7M |
| RICHMOND TIMOTHY J. | Mar 1, 2024 | Sell | 15,412 | $176.4 | $2.7M |
| RICHMOND TIMOTHY J. | Mar 1, 2024 | Sell | 20,127 | $177.71 | $3.6M |
| RICHMOND TIMOTHY J. | Mar 1, 2024 | Sell | 30,288 | $177.71 | $5.4M |
| RICHMOND TIMOTHY J. | Mar 1, 2024 | Sell | 9,853 | $176.35 | $1.7M |
| Buckbee Kevin K | Feb 29, 2024 | Sell | 5,144 | $176.65 | $910,000 |
| Michael Robert A. | Feb 29, 2024 | Sell | 47,319 | $176.46 | $8.3M |
| Michael Robert A. | Feb 29, 2024 | Sell | 21,560 | $176.44 | $3.8M |
| Siatis Perry C | Feb 29, 2024 | Sell | 6,504 | $177.05 | $1.2M |
| Siatis Perry C | Feb 29, 2024 | Sell | 3,387 | $178.04 | $600,000 |
| GONZALEZ RICHARD A | Feb 28, 2024 | Sell | 138,616 | $177.27 | $25M |
| Reents Scott T | Feb 23, 2024 | Sell | 14,140 | $177.44 | $2.5M |
| Siatis Perry C | Feb 23, 2024 | Sell | 13,753 | $177.51 | $2.4M |
| SALEKI-GERHARDT AZITA | Feb 21, 2024 | Sell | 52,870 | $173.71 | $9.2M |
FAQ - Insider Transactions
The most recent insider transaction for AbbVie was conducted by SALEKI-GERHARDT AZITA, who sold 42,370 shares on August 12, 2025 at a price of $198.42 per share.
GONZALEZ RICHARD A has sold the most ABBV stock in the last 2 years, with a total value of $107M.
The total value of insider transactions for AbbVie in the last 2 years is negative, amounting to -$212M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for AbbVie have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
